Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CYFIP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CYFIP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CYFIP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CYFIP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CYFIP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CYFIP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CYFIP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CYFIP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004325419 | Prostate | Tumor | regulation of protein-containing complex assembly | 132/3246 | 428/18723 | 3.32e-12 | 2.78e-10 | 132 |
GO:002260418 | Prostate | Tumor | regulation of cell morphogenesis | 102/3246 | 309/18723 | 1.25e-11 | 9.49e-10 | 102 |
GO:011005319 | Prostate | Tumor | regulation of actin filament organization | 94/3246 | 278/18723 | 1.77e-11 | 1.25e-09 | 94 |
GO:005149517 | Prostate | Tumor | positive regulation of cytoskeleton organization | 78/3246 | 226/18723 | 3.05e-10 | 1.65e-08 | 78 |
GO:003133419 | Prostate | Tumor | positive regulation of protein-containing complex assembly | 80/3246 | 237/18723 | 6.10e-10 | 3.11e-08 | 80 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:005125819 | Prostate | Tumor | protein polymerization | 93/3246 | 297/18723 | 2.22e-09 | 9.58e-08 | 93 |
GO:003227119 | Prostate | Tumor | regulation of protein polymerization | 77/3246 | 233/18723 | 3.76e-09 | 1.54e-07 | 77 |
GO:000726514 | Prostate | Tumor | Ras protein signal transduction | 101/3246 | 337/18723 | 6.29e-09 | 2.44e-07 | 101 |
GO:190165315 | Prostate | Tumor | cellular response to peptide | 104/3246 | 359/18723 | 2.71e-08 | 8.90e-07 | 104 |
GO:003227318 | Prostate | Tumor | positive regulation of protein polymerization | 51/3246 | 138/18723 | 2.78e-08 | 9.10e-07 | 51 |
GO:003253518 | Prostate | Tumor | regulation of cellular component size | 109/3246 | 383/18723 | 3.56e-08 | 1.12e-06 | 109 |
GO:000155815 | Prostate | Tumor | regulation of cell growth | 115/3246 | 414/18723 | 6.40e-08 | 1.88e-06 | 115 |
GO:000815417 | Prostate | Tumor | actin polymerization or depolymerization | 70/3246 | 218/18723 | 6.91e-08 | 1.97e-06 | 70 |
GO:001072013 | Prostate | Tumor | positive regulation of cell development | 88/3246 | 298/18723 | 1.22e-07 | 3.17e-06 | 88 |
GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
GO:003431412 | Prostate | Tumor | Arp2/3 complex-mediated actin nucleation | 21/3246 | 39/18723 | 2.45e-07 | 5.72e-06 | 21 |
GO:003004117 | Prostate | Tumor | actin filament polymerization | 62/3246 | 191/18723 | 2.47e-07 | 5.72e-06 | 62 |
GO:000806416 | Prostate | Tumor | regulation of actin polymerization or depolymerization | 60/3246 | 188/18723 | 7.30e-07 | 1.47e-05 | 60 |
GO:003083317 | Prostate | Tumor | regulation of actin filament polymerization | 56/3246 | 172/18723 | 8.27e-07 | 1.64e-05 | 56 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa051328 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
hsa051309 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa048107 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa051329 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
hsa0513010 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa048108 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa0513210 | Colorectum | CRC | Salmonella infection | 48/1091 | 249/8465 | 2.43e-03 | 1.69e-02 | 1.15e-02 | 48 |
hsa0513011 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa048109 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa0513211 | Colorectum | CRC | Salmonella infection | 48/1091 | 249/8465 | 2.43e-03 | 1.69e-02 | 1.15e-02 | 48 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYFIP1 | SNV | Missense_Mutation | rs748203521 | c.3367N>A | p.Glu1123Lys | p.E1123K | Q7L576 | protein_coding | tolerated(0.06) | benign(0.442) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.1339G>A | p.Glu447Lys | p.E447K | Q7L576 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.1986N>C | p.Glu662Asp | p.E662D | Q7L576 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.3055G>A | p.Val1019Met | p.V1019M | Q7L576 | protein_coding | tolerated(0.08) | possibly_damaging(0.873) | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.2717G>T | p.Arg906Leu | p.R906L | Q7L576 | protein_coding | tolerated(0.24) | benign(0.175) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CYFIP1 | SNV | Missense_Mutation | rs761297983 | c.29N>T | p.Ala10Val | p.A10V | Q7L576 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.506N>T | p.Ala169Val | p.A169V | Q7L576 | protein_coding | deleterious(0.03) | benign(0.057) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CYFIP1 | SNV | Missense_Mutation | novel | c.2357G>A | p.Arg786Gln | p.R786Q | Q7L576 | protein_coding | deleterious(0.01) | possibly_damaging(0.647) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CYFIP1 | SNV | Missense_Mutation | novel | c.1066N>A | p.His356Asn | p.H356N | Q7L576 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
CYFIP1 | insertion | Nonsense_Mutation | novel | c.2129_2130insCCTTCCCTG | p.Ile710_Phe711insLeuProTer | p.I710_F711insLP* | Q7L576 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |